BHARAT BIOTECH
COVID-19 Vaccine Latest Update: WHO Accepts Bharat Biotech's Expression of Interest for COVAXIN Emergency Use Listing, Awaiting Phase-3 Trials Data
News Reports on Bharat Biotech Submitting Phase-3 Data of COVID-19 Vaccine Covaxin to WHO Is Incorrect and Lacks Any Evidence, Says Company
PETA Urges DCGI to Replace Newborn Calf Serum Method for COVID-19 Vaccine 'Covaxin' Production
Calf Serum Used Only in Manufacturing of Viral Vaccines; COVID-19 Vaccine Covaxin Is Free From All Impurities: Bharat Biotech
COVID-19 Vaccine Price: Supply of Covaxin to Indian Govt at Rs 150/Dose Not Sustainable, Says Bharat Biotech
COVID-19 Vaccine Covaxin at Rs 150 Per Dose to Central Govt Not Sustainable in Long Run, Says Bharat Biotech
COVID-19 Vaccine Covaxin's Scientific Standards & Commitment is Transparent, Says Bharat Biotech JMD Suchitra Ella
COVID-19 Vaccine: Bharat Biotech To Carry Out Clinical Trials In the United States To Support Marketing Application For Covaxin
FDA Rejects EUA for Covaxin, 'Suggests' Biologics Licence Application Route For Approval in US
Covishield, Covaxin, Sputnik V Price Capped For Private Hospitals; Here’s How Much They Will Cost Now
COVID-19 Vaccine Update: Bharat Biotech's COVAXIN Offers Protection Against Beta And Delta Variants of Coronavirus, Claims Study
COVID-19 Vaccination: 25 Crore Doses Of Covishield And 19 Crore Of Covaxin To Be Procured To Achieve Universalization Of Vaccination
After AIIMS Patna, AIIMS Delhi To Start Screening for Clinical Trials of Covaxin on Children From June 7
Google Trends